Healthcare Sector

CGEM

Market Tracker

$10.50
+0.82
(+8.47%)
9:20 pm
Next Earnings: (est.) 08/11/23 12:00 am
  • CGEM (Selected)

    Cullinan Oncology, Inc.

CGEM Support / Resistance Levels

Loading Data..
WhaleStream

15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.

CGEM Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

CGEM Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

CGEM Dark Pool and Public Equity Key Price Levels

Loading Data..

Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.

CGEM Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

CGEM Largest 1-Day Open Interest Movements

Expires Type Strike OI Change Percent
01/16/2026 CALL $10.00 1,049 +355 +51.15%
01/16/2026 PUT $12.50 56 +56
02/20/2026 CALL $14.00 50 +50
02/20/2026 CALL $10.00 7 +7
02/20/2026 CALL $9.00 5 +5
01/16/2026 PUT $9.00 53 +2 +3.92%
12/18/2026 PUT $10.00 0 0
12/18/2026 PUT $12.00 6 0
12/18/2026 PUT $15.00 5 0
12/18/2026 PUT $20.00 0 0
12/18/2026 PUT $25.00 0 0
04/17/2026 CALL $11.00 119 -2 -1.65%

Contracts with largest changes in open interest from the previous trading day to the current/most recent.

CGEM Major Holders

Name Pct Held Shares Total
Vanguard Total Stock Market Index Fund 2.34% 922.53k 9.57M
Vanguard Small-Cap Index Fund 2.10% 825.39k 8.56M
iShares Russell 2000 ETF 1.61% 633.59k 6.57M
Vanguard Small-Cap Growth Index Fund 1.21% 475.49k 4.93M
Franklin Strategic Series-Franklin Small Cap Growth Fund 1.09% 427.5k 4.43M
Vanguard Extended Market Index Fund 0.92% 360.62k 3.74M
iShares Russell 2000 Value ETF 0.77% 302.37k 3.14M
Avantis U.S. Small Cap Value ETF 0.73% 287.21k 2.98M
Fidelity Small Cap Index Fund 0.64% 253.23k 2.63M
iShares NASDAQ Biotechnology ETF 0.60% 236.28k 2.45M

CGEM News

  • Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

    10/25 11:01 am

    GlobeNewswire Inc.

    Read more
  • Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

    09/12 07:00 am

    GlobeNewswire Inc.

    Read more
  • Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    08/07 07:00 am

    GlobeNewswire Inc.

    Read more
  • Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

    04/16 07:00 am

    GlobeNewswire Inc.

    Read more
  • Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

    02/27 08:00 am

    GlobeNewswire Inc.

    Read more
  • Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

    11/14 11:01 am

    GlobeNewswire Inc.

    Read more
  • Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

    09/25 08:04 am

    Benzinga

    Read more
  • Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

    09/14 04:15 am

    GlobeNewswire Inc.

    Read more
  • Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

    06/01 07:00 am

    GlobeNewswire Inc.

    Read more
  • Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

    05/24 08:00 am

    GlobeNewswire Inc.

    Read more
  • Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

    05/23 05:04 pm

    GlobeNewswire Inc.

    Read more
  • Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

    05/15 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

    04/29 07:00 am

    GlobeNewswire Inc.

    Read more
  • Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

    04/24 02:29 pm

    Benzinga

    Read more
  • Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

    04/24 10:09 am

    GlobeNewswire Inc.

    Read more
  • Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

    04/17 01:36 pm

    Benzinga

    Read more
  • United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday

    04/17 10:55 am

    Benzinga

    Read more
  • Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    04/16 02:17 pm

    Benzinga

    Read more
  • Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

    04/16 01:32 pm

    Benzinga

    Read more
  • UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday

    04/16 10:15 am

    Benzinga

    Read more
  • Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

    03/14 07:00 am

    GlobeNewswire Inc.

    Read more
  • Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?

    03/04 09:18 am

    Zacks Investment Research

    Read more
  • Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

    03/01 08:00 am

    GlobeNewswire Inc.

    Read more
  • Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

    02/27 12:51 pm

    Zacks Investment Research

    Read more
  • Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?

    02/26 12:28 pm

    Zacks Investment Research

    Read more
  • Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?

    02/21 12:24 pm

    Zacks Investment Research

    Read more
  • Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

    02/20 02:32 pm

    Zacks Investment Research

    Read more
  • Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?

    02/19 12:01 pm

    Zacks Investment Research

    Read more
  • Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

    01/30 08:52 am

    Benzinga

    Read more
  • Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    12/18 05:53 pm

    GlobeNewswire Inc.

    Read more
  • Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

    12/14 05:30 pm

    GlobeNewswire Inc.

    Read more
  • Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

    11/03 12:01 pm

    GlobeNewswire Inc.

    Read more
  • Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023

    10/06 11:00 am

    Benzinga

    Read more
  • Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

    08/10 07:00 am

    GlobeNewswire Inc.

    Read more
  • Analyst Ratings for Cullinan Oncology

    08/09 02:00 pm

    Benzinga

    Read more
  • Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

    08/09 07:00 am

    GlobeNewswire Inc.

    Read more
  • Cullinan Oncology to Participate in Upcoming Investor Conferences

    07/31 08:00 am

    GlobeNewswire Inc.

    Read more
  • Analyst Ratings for Cullinan Oncology

    07/07 08:04 am

    Benzinga

    Read more
  • Analyst Expectations for Cullinan Oncology's Future

    06/15 04:01 pm

    Benzinga

    Read more
  • Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023

    06/15 11:01 am

    Benzinga

    Read more
  • Expert Ratings for Cullinan Oncology

    06/15 08:01 am

    Benzinga

    Read more
  • Why Shares of Cullinan Oncology Jumped This Week

    06/09 04:07 pm

    The Motley Fool

    Read more
  • 4 Analysts Have This to Say About Cullinan Oncology

    05/26 09:02 am

    Benzinga

    Read more
  • Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

    05/25 05:00 pm

    GlobeNewswire Inc.

    Read more
  • Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

    04/26 10:08 am

    GlobeNewswire Inc.

    Read more
  • Cullinan: Trading Way Below Cash

    04/05 01:28 am

    Seeking Alpha

    Read more
  • What 4 Analyst Ratings Have To Say About Cullinan Oncology

    03/27 12:00 pm

    Benzinga

    Read more
  • Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

    03/27 07:00 am

    GlobeNewswire Inc.

    Read more
  • Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

    03/14 04:35 pm

    GlobeNewswire Inc.

    Read more
  • Celularity (CELU) to Report Q4 Earnings: What's in the Cards?

    03/06 11:54 am

    Zacks Investment Research

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: